Oric Pharmaceuticals, Inc.
ORIC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796280
In the last 90 days, Oric Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 4 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; Viking Global Investors is the only superinvestor holding it.
Holders of 5% or more of ORIC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Oric Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Nextech Crossover I GP S.a r.l. | 13G/A | 8.40%7.16M shares | – | Jul 7, 20233 filings | Aug 14, 2025 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G/A | 7.80%8.26M shares | −2.19 ppfrom 9.99% | Jan 30, 20244 filings | May 15, 2026 | SEC |
| EcoR1 Capital, LLC | 13G | 6.90%6.73M shares | – | Feb 16, 20216 filings | Aug 5, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.60%5.47M shares | +1.40 ppfrom 4.20% | Oct 22, 20244 filings | Jan 21, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 5.40%5.39M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
60 Schedule 13D and 13G filings on Oric Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 11, 2022 | Column Group II, LP | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 2, 2022 | Victory Capital Management Inc | 13GOld format | – | New | – | SEC |
| Aug 12, 2021 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Mar 22, 2021 | OrbiMed Advisors LLC | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Column Group II, LP | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 2, 20213:13 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
4 notices from officers, directors and other affiliates planning to sell Oric Pharmaceuticals, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Mar 6, 20244:25 PM ET | Jacob ChackoDirector | 40.0K | $648.4K | Mar 6, 202410b5-1 | J.P. Morgan Securities LLC | SEC |
| Feb 6, 20244:05 PM ET | Jacob ChackoDirector | 40.0K | $480.0K | Feb 6, 202410b5-1 | J.P. Morgan Securities LLC | SEC |
| Jul 5, 20234:07 PM ET | Jacob ChackoDirector | 20.0K | $160.0K | Jul 5, 202310b5-1 | J.P. Morgan Securities LLC | SEC |
| Jun 26, 20236:25 PM ET | Jacob ChackoAffiliate | 20.0K | $160.6K | Jun 26, 202310b5-1 | J.P. Morgan Securities LLC | SEC |